IKT · NASDAQ
Inhibikase Therapeutics (IKT) Stock Price & Fundamentals
Inhibikase Therapeutics (IKT) closed at $540.94 on Oct 9, 2026, down 0.46% from the previous close of $543.45.
Share price, past year
1Y +22.40%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $540.94 |
| Sep 30, 2026 | $549.03 |
| Aug 31, 2026 | $537.07 |
| Jul 31, 2026 | $524.21 |
| Jun 30, 2026 | $534.23 |
| May 29, 2026 | $513.77 |
| Apr 30, 2026 | $496.33 |
| Mar 31, 2026 | $475.58 |
| Feb 27, 2026 | $471.24 |
| Jan 30, 2026 | $484.75 |
| Dec 31, 2025 | $469.17 |
| Nov 28, 2025 | $468.58 |
| Oct 31, 2025 | $448.06 |
Key statistics
- Market cap
- $71.42B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.44
- Revenue (TTM)
- —
- Net income (TTM)
- −$60.64M
- Shares outstanding
- 132M
- Dividend yield
- —
- 52-week range
- $438.07 – $573.07
Inhibikase Therapeutics's market cap is $71.42B, based on a share price of $540.94 and 132M shares outstanding as of Jun 30, 2026.
Financials
Inhibikase Therapeutics reported revenue of $0.00 for fiscal 2024, down 100.00% from fiscal 2023.
Inhibikase Therapeutics reported a net loss of $48.26M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2024ended Dec 31, 2024 | $0.00 | −100.0% | −$27.52M | — | −$1.16 | −$19.15M |
| FY2023ended Dec 31, 2023 | $260.50K | +111.0% | −$19.03M | −7,304.7% | −$3.16 | −$18.10M |
| FY2022ended Dec 31, 2022 | $123.44K | −96.0% | −$18.05M | −14,625.9% | −$3.74 | −$17.59M |
| FY2021ended Dec 31, 2021 | $3.10M | +343.9% | −$14.79M | −476.9% | −$0.7081 | −$14.30M |
| FY2020ended Dec 31, 2020 | $698.47K | — | −$2.85M | −407.7% | −$0.306 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | −$19.59M | −$0.11 |
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$16.38M | −$0.10 |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$11.93M | −$0.13 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$9.92M | −$0.11 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$13.68M | −$0.15 |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$12.13M | $0.88 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$5.78M | −$0.65 |
| Q2 FY2024ended Jun 30, 2024 | $0.00 | — | — |
Company profile
- Name
- Inhibikase Therapeutics, Inc.
- Ticker
- IKT
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 1000 N. West Street, Suite 1200, Wilmington, DE 19801
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001750149
Recent SEC filings
- Sep 8, 2026
- Aug 26, 2026
- Aug 11, 2026
- Aug 11, 2026
- Jul 29, 2026
- Jul 23, 2026
- Jul 14, 2026
- Jun 29, 2026
Frequently asked questions
What is Inhibikase Therapeutics's stock price?
Inhibikase Therapeutics (IKT) closed at $540.94 on Oct 9, 2026, down 0.46% from the previous close of $543.45.
What is Inhibikase Therapeutics's market cap?
Inhibikase Therapeutics's market cap is $71.42B, based on a share price of $540.94 and 132M shares outstanding as of Jun 30, 2026.
How much revenue does Inhibikase Therapeutics make?
Inhibikase Therapeutics reported revenue of $0.00 for fiscal 2024, down 100.00% from fiscal 2023.
Does Inhibikase Therapeutics pay a dividend?
Inhibikase Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Inhibikase Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures